The global chronic cough market is expected to reach US$ 9, 854.8 million by 2027 from US$ 5, 430.0 million in 2019; it is estimated to grow at a CAGR of 7.8% from 2020 to 2027. The market growth is attributed to the key factors such as increasing rising incidences of chronic cough and growing product developments to treat chronic cough. On the other hand, product recall is the major factor, which is likely to affect the market growth negatively during the forecast period.
The developments in the pharmaceutical and biopharmaceutical industry for the drugs that can treat chronic cough are likely to lead the market growth. Additionally, there is a rise in the numbers of pharmaceutical companies across the world. Several startups across the globe are involved in the product development for chronic cough. For instance, in May 2020, BELLUS Health Inc., a biopharmaceutical company, has developed novel therapeutics for the chronic cough and other hypersensitization-related disorders. The company is constantly engaged in product development and has recently conducted a virtual key opinion leader (KOL) meeting to discuss the developments regarding chronic cough on 27 May 2020. Specifically, the meeting covered the developmental aspects regarding phase 2 RELIEF trial of BLU-5937 in chronic refractory cough. The company is looking forward to releasing data of clinical trials for RELIEF in June or July 2020.
The universities are engaged in research work for the development of new drugs to cure chronic cough. For instance, in February 2020, the results of two clinical trials phases for a new drug, Gefapixant were releases. The researchers at the University of Manchester developed Gefapixant. The pharmaceutical market leader Merck & Co., Inc. (MSD) funded the clinical trials, in which the results showed that a dose of 7.5 mg reduced the cough by 52%, 20mg by 52%, and 50mg by 67% from baseline. The drug targets P2X3 receptors in the nerves that control coughing. Therefore, the developments by the pharmaceutical companies to treat chronic cough are likely to support the market growth during the forecast period.
The global chronic cough market is segmented by drug class, route of administration, and distribution channel. Based on drug class, the market is segmented into antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and other drug class. The combination drug segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR during the forecast period. Based on route of administration, the chronic cough market has been segmented into oral, injections, inhalation, and other route of administration. The oral segment held the largest share of the market in 2019; whereas, the inhalation segment is estimated to register the highest CAGR during the forecast period. Based on distribution channel, the chronic cough market has been segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment held largest market share in 2019. However, online pharmacy is expected to grow at a fastest CAGR during forecast period.
The American College of Chest Physicians, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Dubai Health Authority, European Respiratory Society, and Japanese Respiratory Society are among the essential secondary sources refereed to while preparing this report.
Reasons to Buy
The developments in the pharmaceutical and biopharmaceutical industry for the drugs that can treat chronic cough are likely to lead the market growth. Additionally, there is a rise in the numbers of pharmaceutical companies across the world. Several startups across the globe are involved in the product development for chronic cough. For instance, in May 2020, BELLUS Health Inc., a biopharmaceutical company, has developed novel therapeutics for the chronic cough and other hypersensitization-related disorders. The company is constantly engaged in product development and has recently conducted a virtual key opinion leader (KOL) meeting to discuss the developments regarding chronic cough on 27 May 2020. Specifically, the meeting covered the developmental aspects regarding phase 2 RELIEF trial of BLU-5937 in chronic refractory cough. The company is looking forward to releasing data of clinical trials for RELIEF in June or July 2020.
The universities are engaged in research work for the development of new drugs to cure chronic cough. For instance, in February 2020, the results of two clinical trials phases for a new drug, Gefapixant were releases. The researchers at the University of Manchester developed Gefapixant. The pharmaceutical market leader Merck & Co., Inc. (MSD) funded the clinical trials, in which the results showed that a dose of 7.5 mg reduced the cough by 52%, 20mg by 52%, and 50mg by 67% from baseline. The drug targets P2X3 receptors in the nerves that control coughing. Therefore, the developments by the pharmaceutical companies to treat chronic cough are likely to support the market growth during the forecast period.
The global chronic cough market is segmented by drug class, route of administration, and distribution channel. Based on drug class, the market is segmented into antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and other drug class. The combination drug segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR during the forecast period. Based on route of administration, the chronic cough market has been segmented into oral, injections, inhalation, and other route of administration. The oral segment held the largest share of the market in 2019; whereas, the inhalation segment is estimated to register the highest CAGR during the forecast period. Based on distribution channel, the chronic cough market has been segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment held largest market share in 2019. However, online pharmacy is expected to grow at a fastest CAGR during forecast period.
The American College of Chest Physicians, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Dubai Health Authority, European Respiratory Society, and Japanese Respiratory Society are among the essential secondary sources refereed to while preparing this report.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the chronic cough market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global chronic cough market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. Chronic Cough Market - Market Landscape
5. Chronic Cough Market - Key Market Dynamics
6. Chronic Cough Market - Global Analysis
7. Chronic Cough Market Analysis - By Drug Class
8. Chronic Cough Market - By Route of Administration
9. Chronic Cough Market - By Distribution Channel
10. Chronic Cough Market - Geographic Analysis
11. Impact of COVID-19 Pandemic on Global Chronic cough Market
12. Chronic Cough Market -Industry Landscape
13. COMPANY PROFILES
14. Appendix
Companies Mentioned
A selection of companies mentioned in this report includes:
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline plc.
- Bayer AG
- Mylan N.V.
- Amneal Pharmaceuticals, Inc.
- Cipla Inc.
- Reckitt Benckiser Group plc.
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Ltd
